2025 Q4 -tulosraportti
Vain PDF
90 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·35 min sitten · MuokattuCircio is facing an autumn full of results. If one takes a look back in time, from when the news about the collaboration with Big Pharma came in November 2025 until July 2026, there are a few things that strike one. A number of news items about collaboration projects etc. have emerged, but limited concrete results have been released. New collaborations: Nov 2025 - Feasibility study CNS /AAVV 2026 January - University of Texas - vaccines/infectious diseases March - United Immunity - CAR-M cell therapy April - Acuitas - new LNP - CAR-T - CD8+ and CD4+ t-cell April - TraffikGen - gene/ car-t - peptide based May - AaviGen - heart - aav capsides June - GenAssist - muscle and CAR-T - aav based - 2nd generation June - TcellTech - CAR-T - CD19 cell As a result of these agreements, 3 share issues, and the company having received completely different financing, plans have evidently been affected, and no concrete results have been released. After updated data in heart and eye at the February 26th presentation (and the follow-up of this at ASGCT in May), no concrete results have actually been released. In e.g. CNS after the circVec 2.1 studies and the result in August 2025, things have stalled. They have said that the development between the circVec variants resembles the eye - continuously better effect with new circVec variants. The feasibility study has put a lid on results from 3.2 and 4.0 in CNS, which they were already working on last August. We only know that this is going better than expected. Disease models in eye and heart were in the pipeline. AAViGEN's fantastically precise AAV capsides in the heart have probably completely turned around the strategy in the heart project. Danon disease, which was on the agenda last autumn, is probably gone? It had no commercial purpose, about 1500 patients in the world -- it was only meant to document the circVec technology. Publication of CAR-T construct POC - has been postponed. It's not surprising when one looks at all the collaboration agreements across all the different variants in CAR-T and CAR-M. But - a CAR-T construct must exist, and it must have impressed several, as there has been a queue for collaboration and combining technologies. EYE - it is silent about, despite fantastic results 50x. They have talked about needing to conduct studies in primate species - monkeys or similar - to substantiate data. I believe a collaboration agreement will come there soon. We can interpret the silence as something being underway. We have indications that there has been contact for a long time between Circio and its collaboration partners before the agreements were announced. The technology has probably been tested/evaluated by both before an agreement was entered into. Among other things, in connection with the TraffikGen agreement that came at the end of April 2026, an article later appeared, published 2 months earlier in February 2026, which mentioned a collaboration with a Norwegian biotech company. Much has probably already been done in these collaborations. It looks like a busy autumn for Circio shareholders.
- ·4 t sittenI have a question for those of you who have calculated the valuation of Circio. I see everything from 20–30 kroner to over 200 kroner per share being mentioned. Personally, I find it difficult to know what is actually realistic. For my part, a doubling from today's price around 7 would have been a very good investment. Should the company succeed properly, I think that 40–50 kroner would have been a fantastic outcome. So I am genuinely curious: What do you think is a realistic price target if the case succeeds? And perhaps even more importantly: How do you calculate it? Do you base it on comparable acquisitions like Orbital and Orna, expected licensing agreements, DCF, market size, or something completely different? I am most interested in the reasoning itself. It's easy to write a high number, but far more interesting to understand what assumptions lie behind it.
·4 t sittenThose of you who have the roadmap available, what is the next trigger for crna? At least calendar-wise
This one has died out. The euphoria is gone. No stock exchange announcements and the turnover is drying up. Good to have moved over to oil. Will come back again when something happens. Good luck!
·17 t sittenThe latest edition of BioWorld from July 13, 2026 brings two significant scientific news items that immediately capture the attention of those following biological gene therapy. At first glance, major breakthroughs in brain diseases and advanced cell therapy might seem like increased competition. The truth is that these are projects that do not represent any direct competition for Circio's patents, as none of these players own a universal circular RNA expression vector. They are developing specific therapeutic targets, but they lack the molecular engine to keep them going. The industry's biggest bottlenecks become visible Yesterday's newsletter shows that medical research is on the verge of cracking the biological codes for both Alzheimer's and severe allergies – but both of these new treatment methods hit exactly the same biological wall. They lack a method to keep gene instructions active in cells over time without permanently integrating into the patient's DNA. The biological mechanisms behind these two news items show why Circio's circVec platform hits the bullseye: 1. "The Tau Era" requires durability – Linear RNA collapses in the brain At the world's largest dementia conference, AAIC 2026, it is now established that the focus is shifting from amyloid plaques to the tau protein. What is the tau problem? In a healthy brain, tau proteins function as "railway sleepers" that stabilize the transport system inside brain cells. In Alzheimer's, these sleepers collapse and tangle into toxic threads (tau-tangles) that kill neurons. The treatment method: To stop this, a genetic instruction must be delivered that tells brain cells to stop producing the defective tau protein (so-called tau-lowering). The biological delivery problem: Brain cells (neurons) almost never divide; they are meant to last a lifetime. If one tries to deliver this genetic instruction with ordinary, linear mRNA, the cell's own enzymes (nucleases) will cut it into pieces within a few hours. Giving the patient frequent, repetitive injections directly into the cerebral cortex or spinal cord is clinically impossible. Why circVec is the solution: Since Circio's RNA sequence is circular, it has no free ends where enzymes can attach to start degradation. The circVec-AAV vector can thus remain stable inside the non-dividing brain cells and continuously pump out the tau-lowering recipe for months and years after a single dose. This is exactly the biological mechanism being tested in Circio's ongoing in vivo study in the brain (CNS) with their global "top-5" pharma partner, where data is now landing in the second half of 2026. 2. CAR-T against allergy (Tregs) requires controlled lifespan The second major news item describes how researchers have programmed regulatory T-cells (Tregs) with artificial receptors (CARs) to recognize and block birch pollen directly in the body. What are CAR-Tregs against allergy? Traditional CAR-T programs immune cells to kill cancer cells. Here, the opposite is done: Suppressive T-cells (Tregs) are programmed to seek out areas where pollen exposure causes an allergic inflammation, and then to calm down the immune system's violent overreaction. The biological problem: T-cells are extremely potent biological machines. If a traditional virus is used to permanently insert the new CAR recipe into the cell's own DNA, there is a risk that these cells will live forever in the patient. This can lead to the immune system being permanently weakened against other, vital pathogens. If, on the other hand, ordinary linear mRNA is used, the protein expression becomes so short-lived (1–2 days) that the cells stop working before the pollen season has even properly begun. Why circVec is the solution: With circular RNA delivered via the non-viral particles Circio is now testing (such as Tcelltech's nanoSMAR platform or Acuitas' lipid nanoparticles), T-cells can be programmed to produce the protective CAR receptors for exactly 3–4 weeks – precisely enough to cover the critical pollen season – before the molecule naturally and safely degrades without leaving permanent changes in the patient's genetic material. The scientific breakthroughs presented at this year's major conferences create an enormous demand for tools that can deliver controlled, robust, and long-lasting gene expression outside the liver. Those trying to lower tau in the brain, or stop allergy with CAR-Tregs, have found the biological targets, but they lack the biological durability that Circio's circVec portfolio is designed to provide them.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
90 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·35 min sitten · MuokattuCircio is facing an autumn full of results. If one takes a look back in time, from when the news about the collaboration with Big Pharma came in November 2025 until July 2026, there are a few things that strike one. A number of news items about collaboration projects etc. have emerged, but limited concrete results have been released. New collaborations: Nov 2025 - Feasibility study CNS /AAVV 2026 January - University of Texas - vaccines/infectious diseases March - United Immunity - CAR-M cell therapy April - Acuitas - new LNP - CAR-T - CD8+ and CD4+ t-cell April - TraffikGen - gene/ car-t - peptide based May - AaviGen - heart - aav capsides June - GenAssist - muscle and CAR-T - aav based - 2nd generation June - TcellTech - CAR-T - CD19 cell As a result of these agreements, 3 share issues, and the company having received completely different financing, plans have evidently been affected, and no concrete results have been released. After updated data in heart and eye at the February 26th presentation (and the follow-up of this at ASGCT in May), no concrete results have actually been released. In e.g. CNS after the circVec 2.1 studies and the result in August 2025, things have stalled. They have said that the development between the circVec variants resembles the eye - continuously better effect with new circVec variants. The feasibility study has put a lid on results from 3.2 and 4.0 in CNS, which they were already working on last August. We only know that this is going better than expected. Disease models in eye and heart were in the pipeline. AAViGEN's fantastically precise AAV capsides in the heart have probably completely turned around the strategy in the heart project. Danon disease, which was on the agenda last autumn, is probably gone? It had no commercial purpose, about 1500 patients in the world -- it was only meant to document the circVec technology. Publication of CAR-T construct POC - has been postponed. It's not surprising when one looks at all the collaboration agreements across all the different variants in CAR-T and CAR-M. But - a CAR-T construct must exist, and it must have impressed several, as there has been a queue for collaboration and combining technologies. EYE - it is silent about, despite fantastic results 50x. They have talked about needing to conduct studies in primate species - monkeys or similar - to substantiate data. I believe a collaboration agreement will come there soon. We can interpret the silence as something being underway. We have indications that there has been contact for a long time between Circio and its collaboration partners before the agreements were announced. The technology has probably been tested/evaluated by both before an agreement was entered into. Among other things, in connection with the TraffikGen agreement that came at the end of April 2026, an article later appeared, published 2 months earlier in February 2026, which mentioned a collaboration with a Norwegian biotech company. Much has probably already been done in these collaborations. It looks like a busy autumn for Circio shareholders.
- ·4 t sittenI have a question for those of you who have calculated the valuation of Circio. I see everything from 20–30 kroner to over 200 kroner per share being mentioned. Personally, I find it difficult to know what is actually realistic. For my part, a doubling from today's price around 7 would have been a very good investment. Should the company succeed properly, I think that 40–50 kroner would have been a fantastic outcome. So I am genuinely curious: What do you think is a realistic price target if the case succeeds? And perhaps even more importantly: How do you calculate it? Do you base it on comparable acquisitions like Orbital and Orna, expected licensing agreements, DCF, market size, or something completely different? I am most interested in the reasoning itself. It's easy to write a high number, but far more interesting to understand what assumptions lie behind it.
- ·4 t sittenThose of you who have the roadmap available, what is the next trigger for crna? At least calendar-wiseThis one has died out. The euphoria is gone. No stock exchange announcements and the turnover is drying up. Good to have moved over to oil. Will come back again when something happens. Good luck!
- ·17 t sittenThe latest edition of BioWorld from July 13, 2026 brings two significant scientific news items that immediately capture the attention of those following biological gene therapy. At first glance, major breakthroughs in brain diseases and advanced cell therapy might seem like increased competition. The truth is that these are projects that do not represent any direct competition for Circio's patents, as none of these players own a universal circular RNA expression vector. They are developing specific therapeutic targets, but they lack the molecular engine to keep them going. The industry's biggest bottlenecks become visible Yesterday's newsletter shows that medical research is on the verge of cracking the biological codes for both Alzheimer's and severe allergies – but both of these new treatment methods hit exactly the same biological wall. They lack a method to keep gene instructions active in cells over time without permanently integrating into the patient's DNA. The biological mechanisms behind these two news items show why Circio's circVec platform hits the bullseye: 1. "The Tau Era" requires durability – Linear RNA collapses in the brain At the world's largest dementia conference, AAIC 2026, it is now established that the focus is shifting from amyloid plaques to the tau protein. What is the tau problem? In a healthy brain, tau proteins function as "railway sleepers" that stabilize the transport system inside brain cells. In Alzheimer's, these sleepers collapse and tangle into toxic threads (tau-tangles) that kill neurons. The treatment method: To stop this, a genetic instruction must be delivered that tells brain cells to stop producing the defective tau protein (so-called tau-lowering). The biological delivery problem: Brain cells (neurons) almost never divide; they are meant to last a lifetime. If one tries to deliver this genetic instruction with ordinary, linear mRNA, the cell's own enzymes (nucleases) will cut it into pieces within a few hours. Giving the patient frequent, repetitive injections directly into the cerebral cortex or spinal cord is clinically impossible. Why circVec is the solution: Since Circio's RNA sequence is circular, it has no free ends where enzymes can attach to start degradation. The circVec-AAV vector can thus remain stable inside the non-dividing brain cells and continuously pump out the tau-lowering recipe for months and years after a single dose. This is exactly the biological mechanism being tested in Circio's ongoing in vivo study in the brain (CNS) with their global "top-5" pharma partner, where data is now landing in the second half of 2026. 2. CAR-T against allergy (Tregs) requires controlled lifespan The second major news item describes how researchers have programmed regulatory T-cells (Tregs) with artificial receptors (CARs) to recognize and block birch pollen directly in the body. What are CAR-Tregs against allergy? Traditional CAR-T programs immune cells to kill cancer cells. Here, the opposite is done: Suppressive T-cells (Tregs) are programmed to seek out areas where pollen exposure causes an allergic inflammation, and then to calm down the immune system's violent overreaction. The biological problem: T-cells are extremely potent biological machines. If a traditional virus is used to permanently insert the new CAR recipe into the cell's own DNA, there is a risk that these cells will live forever in the patient. This can lead to the immune system being permanently weakened against other, vital pathogens. If, on the other hand, ordinary linear mRNA is used, the protein expression becomes so short-lived (1–2 days) that the cells stop working before the pollen season has even properly begun. Why circVec is the solution: With circular RNA delivered via the non-viral particles Circio is now testing (such as Tcelltech's nanoSMAR platform or Acuitas' lipid nanoparticles), T-cells can be programmed to produce the protective CAR receptors for exactly 3–4 weeks – precisely enough to cover the critical pollen season – before the molecule naturally and safely degrades without leaving permanent changes in the patient's genetic material. The scientific breakthroughs presented at this year's major conferences create an enormous demand for tools that can deliver controlled, robust, and long-lasting gene expression outside the liver. Those trying to lower tau in the brain, or stop allergy with CAR-Tregs, have found the biological targets, but they lack the biological durability that Circio's circVec portfolio is designed to provide them.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
90 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·35 min sitten · MuokattuCircio is facing an autumn full of results. If one takes a look back in time, from when the news about the collaboration with Big Pharma came in November 2025 until July 2026, there are a few things that strike one. A number of news items about collaboration projects etc. have emerged, but limited concrete results have been released. New collaborations: Nov 2025 - Feasibility study CNS /AAVV 2026 January - University of Texas - vaccines/infectious diseases March - United Immunity - CAR-M cell therapy April - Acuitas - new LNP - CAR-T - CD8+ and CD4+ t-cell April - TraffikGen - gene/ car-t - peptide based May - AaviGen - heart - aav capsides June - GenAssist - muscle and CAR-T - aav based - 2nd generation June - TcellTech - CAR-T - CD19 cell As a result of these agreements, 3 share issues, and the company having received completely different financing, plans have evidently been affected, and no concrete results have been released. After updated data in heart and eye at the February 26th presentation (and the follow-up of this at ASGCT in May), no concrete results have actually been released. In e.g. CNS after the circVec 2.1 studies and the result in August 2025, things have stalled. They have said that the development between the circVec variants resembles the eye - continuously better effect with new circVec variants. The feasibility study has put a lid on results from 3.2 and 4.0 in CNS, which they were already working on last August. We only know that this is going better than expected. Disease models in eye and heart were in the pipeline. AAViGEN's fantastically precise AAV capsides in the heart have probably completely turned around the strategy in the heart project. Danon disease, which was on the agenda last autumn, is probably gone? It had no commercial purpose, about 1500 patients in the world -- it was only meant to document the circVec technology. Publication of CAR-T construct POC - has been postponed. It's not surprising when one looks at all the collaboration agreements across all the different variants in CAR-T and CAR-M. But - a CAR-T construct must exist, and it must have impressed several, as there has been a queue for collaboration and combining technologies. EYE - it is silent about, despite fantastic results 50x. They have talked about needing to conduct studies in primate species - monkeys or similar - to substantiate data. I believe a collaboration agreement will come there soon. We can interpret the silence as something being underway. We have indications that there has been contact for a long time between Circio and its collaboration partners before the agreements were announced. The technology has probably been tested/evaluated by both before an agreement was entered into. Among other things, in connection with the TraffikGen agreement that came at the end of April 2026, an article later appeared, published 2 months earlier in February 2026, which mentioned a collaboration with a Norwegian biotech company. Much has probably already been done in these collaborations. It looks like a busy autumn for Circio shareholders.
- ·4 t sittenI have a question for those of you who have calculated the valuation of Circio. I see everything from 20–30 kroner to over 200 kroner per share being mentioned. Personally, I find it difficult to know what is actually realistic. For my part, a doubling from today's price around 7 would have been a very good investment. Should the company succeed properly, I think that 40–50 kroner would have been a fantastic outcome. So I am genuinely curious: What do you think is a realistic price target if the case succeeds? And perhaps even more importantly: How do you calculate it? Do you base it on comparable acquisitions like Orbital and Orna, expected licensing agreements, DCF, market size, or something completely different? I am most interested in the reasoning itself. It's easy to write a high number, but far more interesting to understand what assumptions lie behind it.
- ·4 t sittenThose of you who have the roadmap available, what is the next trigger for crna? At least calendar-wiseThis one has died out. The euphoria is gone. No stock exchange announcements and the turnover is drying up. Good to have moved over to oil. Will come back again when something happens. Good luck!
- ·17 t sittenThe latest edition of BioWorld from July 13, 2026 brings two significant scientific news items that immediately capture the attention of those following biological gene therapy. At first glance, major breakthroughs in brain diseases and advanced cell therapy might seem like increased competition. The truth is that these are projects that do not represent any direct competition for Circio's patents, as none of these players own a universal circular RNA expression vector. They are developing specific therapeutic targets, but they lack the molecular engine to keep them going. The industry's biggest bottlenecks become visible Yesterday's newsletter shows that medical research is on the verge of cracking the biological codes for both Alzheimer's and severe allergies – but both of these new treatment methods hit exactly the same biological wall. They lack a method to keep gene instructions active in cells over time without permanently integrating into the patient's DNA. The biological mechanisms behind these two news items show why Circio's circVec platform hits the bullseye: 1. "The Tau Era" requires durability – Linear RNA collapses in the brain At the world's largest dementia conference, AAIC 2026, it is now established that the focus is shifting from amyloid plaques to the tau protein. What is the tau problem? In a healthy brain, tau proteins function as "railway sleepers" that stabilize the transport system inside brain cells. In Alzheimer's, these sleepers collapse and tangle into toxic threads (tau-tangles) that kill neurons. The treatment method: To stop this, a genetic instruction must be delivered that tells brain cells to stop producing the defective tau protein (so-called tau-lowering). The biological delivery problem: Brain cells (neurons) almost never divide; they are meant to last a lifetime. If one tries to deliver this genetic instruction with ordinary, linear mRNA, the cell's own enzymes (nucleases) will cut it into pieces within a few hours. Giving the patient frequent, repetitive injections directly into the cerebral cortex or spinal cord is clinically impossible. Why circVec is the solution: Since Circio's RNA sequence is circular, it has no free ends where enzymes can attach to start degradation. The circVec-AAV vector can thus remain stable inside the non-dividing brain cells and continuously pump out the tau-lowering recipe for months and years after a single dose. This is exactly the biological mechanism being tested in Circio's ongoing in vivo study in the brain (CNS) with their global "top-5" pharma partner, where data is now landing in the second half of 2026. 2. CAR-T against allergy (Tregs) requires controlled lifespan The second major news item describes how researchers have programmed regulatory T-cells (Tregs) with artificial receptors (CARs) to recognize and block birch pollen directly in the body. What are CAR-Tregs against allergy? Traditional CAR-T programs immune cells to kill cancer cells. Here, the opposite is done: Suppressive T-cells (Tregs) are programmed to seek out areas where pollen exposure causes an allergic inflammation, and then to calm down the immune system's violent overreaction. The biological problem: T-cells are extremely potent biological machines. If a traditional virus is used to permanently insert the new CAR recipe into the cell's own DNA, there is a risk that these cells will live forever in the patient. This can lead to the immune system being permanently weakened against other, vital pathogens. If, on the other hand, ordinary linear mRNA is used, the protein expression becomes so short-lived (1–2 days) that the cells stop working before the pollen season has even properly begun. Why circVec is the solution: With circular RNA delivered via the non-viral particles Circio is now testing (such as Tcelltech's nanoSMAR platform or Acuitas' lipid nanoparticles), T-cells can be programmed to produce the protective CAR receptors for exactly 3–4 weeks – precisely enough to cover the critical pollen season – before the molecule naturally and safely degrades without leaving permanent changes in the patient's genetic material. The scientific breakthroughs presented at this year's major conferences create an enormous demand for tools that can deliver controlled, robust, and long-lasting gene expression outside the liver. Those trying to lower tau in the brain, or stop allergy with CAR-Tregs, have found the biological targets, but they lack the biological durability that Circio's circVec portfolio is designed to provide them.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt